Sanofi teams up with Mer­ck to pair Keytru­da with a next-gen IL-2 can­di­date from the Syn­thorx buy­out

Near­ly a year af­ter snap­ping up a next-gen im­muno-on­col­o­gy can­di­date in its $2.5 bil­lion Syn­thorx buy­out, Sanofi is join­ing forces with Mer­ck to pair the drug with block­buster Keytru­da.

The phar­mas are plan­ning a Phase II tri­al of Sanofi’s non-al­pha IL-2 can­di­date THOR-707 in com­bi­na­tion or se­quenced ad­min­is­tra­tion with Keytru­da for var­i­ous can­cers. While the com­pa­nies are keep­ing mum about the fi­nan­cial terms and tar­gets, they said the tri­als will be Sanofi-spon­sored.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN